Empowered Funds LLC Has $9.27 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Empowered Funds LLC lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 687.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 13,010 shares of the biopharmaceutical company’s stock after purchasing an additional 11,358 shares during the period. Empowered Funds LLC’s holdings in Regeneron Pharmaceuticals were worth $9,267,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of REGN. Forbes J M & Co. LLP boosted its holdings in Regeneron Pharmaceuticals by 150.7% in the fourth quarter. Forbes J M & Co. LLP now owns 519 shares of the biopharmaceutical company’s stock valued at $370,000 after acquiring an additional 312 shares during the last quarter. Kingsview Wealth Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 16.5% in the 4th quarter. Kingsview Wealth Management LLC now owns 1,002 shares of the biopharmaceutical company’s stock valued at $714,000 after purchasing an additional 142 shares during the last quarter. Apollon Wealth Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 8.2% in the 4th quarter. Apollon Wealth Management LLC now owns 1,722 shares of the biopharmaceutical company’s stock valued at $1,227,000 after purchasing an additional 130 shares during the last quarter. Cidel Asset Management Inc. increased its position in shares of Regeneron Pharmaceuticals by 11.4% during the fourth quarter. Cidel Asset Management Inc. now owns 331 shares of the biopharmaceutical company’s stock worth $236,000 after buying an additional 34 shares during the period. Finally, Arcataur Capital Management LLC raised its stake in Regeneron Pharmaceuticals by 34.0% during the fourth quarter. Arcataur Capital Management LLC now owns 1,053 shares of the biopharmaceutical company’s stock worth $750,000 after buying an additional 267 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $710.00 on Monday. The business’s fifty day simple moving average is $715.81 and its 200 day simple moving average is $910.08. The company has a current ratio of 4.73, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12 month low of $642.00 and a 12 month high of $1,211.20. The firm has a market capitalization of $78.02 billion, a P/E ratio of 18.55, a price-to-earnings-growth ratio of 2.38 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the business posted $11.86 EPS. As a group, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 36.67 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.50%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

Analyst Ratings Changes

A number of brokerages have weighed in on REGN. Oppenheimer decreased their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. Evercore ISI decreased their target price on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Citigroup dropped their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. UBS Group downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.